Acute kidney injury in Jamaicans with sickle cell disease hospitalized with COVID‐19 infection

Abstract

AbstractDespite a high occurrence of acute kidney injury (AKI) with COVID‐19 infection, there are no data on its incidence in sickle cell disease (SCD). We performed a single‐center retrospective chart review of persons aged >1 year with SCD, COVID‐19 infection and no prior dialysis requirement hospitalized from June 1, 2020 to May 31, 2022. Demographics, clinical, laboratory characteristics and outcomes were abstracted. AKI was defined using Kidney Disease Improving Global Outcomes (KDIGO) criteria. Of 38 patients meeting study criteria (60.6% female, mean age ± SD 38.6 ± 15.9 years), 3 (7.9%) were COVID vaccinated. Fifty‐five percent (55%) developed AKI with 7.9% (n = 3) requiring dialysis. Participants with AKI were older (44.9 versus 30.8 years, p = 0.005), with a higher proportion having baseline chronic kidney disease (52% versus 0%, p = 0.001). Severe COVID infection [age‐adjusted odds ratio (aOR): 8.93, 95%CI: 1.73‐45.99, p = 0.033], red cell transfusion (aOR 7.92, 1.47‐42.69) and decrease in hemoglobin per unit from baseline (aOR 2.85, 1.24‐2.28) were associated with AKI. Five persons died in hospital, with AKI resulting in higher median length of stay (12 versus 5 days, p = 0.007). Targeted COVID‐19 preventative measures and multinational longitudinal studies to ascertain the impact of AKI and COVID‐19 infection in SCD are needed.